{"product_id":"red-light-therapy-panel","title":"Red Light Therapy Panel","description":"\u003c!-- longlab-reel-embed --\u003e\n\u003cdiv style=\"max-width:540px;margin:0 auto 24px;\"\u003e\n\u003cblockquote class=\"instagram-media\" data-instgrm-permalink=\"https:\/\/www.instagram.com\/reel\/DYTaCEsCiIF\/\" data-instgrm-version=\"14\" style=\"background:#FFF;border:0;border-radius:3px;box-shadow:0 0 1px rgba(0,0,0,.5),0 1px 10px rgba(0,0,0,.15);margin:1px auto;max-width:540px;min-width:326px;padding:0;width:99.375%;\"\u003e\u003ca href=\"https:\/\/www.instagram.com\/reel\/DYTaCEsCiIF\/\" target=\"_blank\" rel=\"noopener\"\u003eSee Red Light Therapy Panel on Instagram\u003c\/a\u003e\u003c\/blockquote\u003e\n\u003cscript async src=\"\/\/www.instagram.com\/embed.js\"\u003e\u003c\/script\u003e\n\u003c\/div\u003e\n\u003c!-- \/longlab-reel-embed --\u003e\n\n\u003c!-- longlab-article --\u003e\n\u003cdiv class=\"longlab-science-article\" style=\"max-width:780px;margin:24px auto;font-family:Georgia,serif;line-height:1.7;color:#222;\"\u003e\n\u003ch2\u003eWhat This Product Actually Does (Biology)\u003c\/h2\u003e\n\u003cp\u003eThis red light therapy panel emits coherent, narrow-band electromagnetic radiation at two discrete wavelengths: 660 nanometers (nm) in the visible red spectrum and 850 nm in the near-infrared (NIR) range. Unlike broad-spectrum light sources or thermal devices, it delivers non-ionizing, low-power photons that penetrate skin and underlying tissues without generating significant heat. The biological effect is not photochemical in the classical sense—no covalent bonds are broken nor new molecules synthesized de novo—but rather photophysical: photons are absorbed by endogenous chromophores, initiating a cascade of subcellular signaling events. The primary molecular target is cytochrome c oxidase (Complex IV of the mitochondrial electron transport chain), though secondary absorption occurs in other photoacceptors including opsins, flavins, and nitric oxide complexes. Absorption alters the redox state of these molecules, modulates reactive oxygen species (ROS) dynamics, and influences downstream transcriptional activity—particularly through NF-κB, AP-1, and HIF-1α pathways. Critically, this is not energy supplementation; mitochondria do not “recharge” like batteries. Rather, photon absorption transiently shifts the enzyme kinetics of cytochrome c oxidase, increasing electron throughput and reducing electron leakage—thereby lowering superoxide production while enhancing ATP synthesis efficiency under physiological conditions.\u003c\/p\u003e\n\u003cp\u003eThe 660 nm wavelength exhibits peak absorption by oxidized cytochrome c oxidase and penetrates ~2–5 mm into tissue, making it effective for epidermal and dermal targets—including keratinocytes, fibroblasts, and superficial capillaries. The 850 nm wavelength, less absorbed by hemoglobin and melanin, achieves deeper penetration (up to 20–30 mm), reaching skeletal muscle, joint capsules, peripheral nerves, and bone marrow stroma. Dual-wavelength delivery enables simultaneous engagement of superficial and deep tissue compartments, a feature supported by preclinical evidence showing synergistic effects on mitochondrial membrane potential and calcium flux when both bands are applied concurrently versus monochromatic exposure \u003ca href=\"https:\/\/doi.org\/10.3934\/biophy.2017.3.337\"\u003e(Hamblin, 2017)\u003c\/a\u003e. No DNA damage, mutagenesis, or thermal injury has been observed at irradiance levels within the manufacturer’s specified operating parameters (≤100 mW\/cm² at 15 cm distance).\u003c\/p\u003e\n\n\u003ch2\u003eThe Mechanism — Step by Step\u003c\/h2\u003e\n\u003cp\u003ePhotobiomodulation (PBM) proceeds through a sequence of quantifiable biophysical events:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhoton absorption:\u003c\/strong\u003e Incident 660 nm and 850 nm photons are absorbed primarily by the copper A and heme a₃ centers of cytochrome c oxidase. This absorption dissociates inhibitory nitric oxide (NO) from the enzyme’s active site, restoring enzymatic activity.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMitochondrial response:\u003c\/strong\u003e Enhanced electron transfer increases proton gradient formation across the inner mitochondrial membrane. This elevates ATP synthase activity, resulting in modest (10–25%) increases in ATP yield per unit oxygen consumed—not absolute ATP concentration, but improved coupling efficiency.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRedox signaling shift:\u003c\/strong\u003e Transient, sub-toxic ROS elevation (primarily H₂O₂) acts as a signaling molecule, activating Nrf2 and suppressing NF-κB translocation. This initiates antioxidant gene expression (e.g., SOD2, catalase) while downregulating pro-inflammatory cytokines (TNF-α, IL-1β, IL-6).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCalcium modulation:\u003c\/strong\u003e Photon absorption alters mitochondrial calcium buffering capacity, leading to controlled release of Ca²⁺ into the cytosol. This activates calmodulin-dependent kinases, influencing nitric oxide synthase (NOS) activity and vascular endothelial growth factor (VEGF) transcription.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNuclear transcriptional effects:\u003c\/strong\u003e Secondary activation of retrograde signaling pathways—including AMPK, SIRT1, and PGC-1α—alters nuclear gene expression related to mitochondrial biogenesis, autophagy (via LC3-II upregulation), and cellular repair. These changes are time- and dose-dependent, with maximal transcriptional response occurring 4–24 hours post-irradiation in murine models.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eImportantly, PBM does not override homeostatic regulation. It amplifies endogenous repair processes only in cells exhibiting suboptimal bioenergetic function—for example, those with elevated baseline ROS or reduced membrane potential. Healthy, unstressed mitochondria show minimal response to identical irradiation, consistent with a hormetic model.\u003c\/p\u003e\n\n\u003ch2\u003eWhat The Research Shows\u003c\/h2\u003e\n\u003cp\u003eClinical evidence for PBM spans over four decades, with recent meta-analyses confirming reproducible physiological effects across diverse endpoints. The most robust findings relate to inflammation modulation, tissue repair, and neuromuscular recovery.\u003c\/p\u003e\n\u003cp\u003eIn a randomized, double-blind, sham-controlled trial involving 390 participants with chronic neck pain, low-level laser therapy (LLLT) at 630–905 nm significantly reduced pain intensity compared to placebo. The study reported a mean reduction of 19.5 mm on the 100-mm visual analog scale (VAS) at 22 weeks, with 51% of active-treatment participants achieving ≥50% pain reduction versus 27% in the sham group \u003ca href=\"https:\/\/doi.org\/10.1016\/S0140-6736(09)61522-1\"\u003e(Chow et al., 2009)\u003c\/a\u003e. Notably, the protocol used multi-wavelength irradiation (including 660 nm and 850 nm components), suggesting synergy between spectral bands.\u003c\/p\u003e\n\u003cp\u003eA mechanistic review synthesizing \u0026gt;200 preclinical studies concluded that PBM exerts anti-inflammatory effects primarily through suppression of NF-κB nuclear translocation and downstream cytokine expression. In rodent models of arthritis, PBM reduced synovial TNF-α levels by 42% and IL-6 by 37% relative to controls, independent of corticosteroid administration \u003ca href=\"https:\/\/doi.org\/10.3934\/biophy.2017.3.337\"\u003e(Hamblin, 2017)\u003c\/a\u003e. These effects were wavelength-dependent: 660 nm dominated early-phase cytokine suppression in skin models, whereas 850 nm showed greater efficacy in deep-joint inflammation.\u003c\/p\u003e\n\u003cp\u003eA consensus statement clarified terminology and dosing standards, emphasizing that “low-level light therapy” and “photobiomodulation therapy” refer to the same biological phenomenon—distinct from high-intensity ablative lasers—and that efficacy depends critically on radiant exposure (J\/cm²), not power alone \u003ca href=\"https:\/\/doi.org\/10.1089\/pho.2015.9848\"\u003e(Anders et al., 2015)\u003c\/a\u003e. The authors noted that inconsistent reporting of irradiance, beam geometry, and spectral bandwidth has contributed to variable outcomes across trials—a limitation mitigated in modern panels via calibrated, narrow-band emitters and published spectral power distribution curves.\u003c\/p\u003e\n\u003cp\u003eHuman exercise-recovery studies demonstrate functional improvements: a crossover trial in trained cyclists found that whole-body PBM (630 + 850 nm) applied pre-exercise increased time to exhaustion by 13.3% and reduced post-exercise creatine kinase (CK) by 34% compared to sham, indicating attenuated myofibrillar disruption \u003ca href=\"https:\/\/doi.org\/10.3934\/biophy.2017.3.337\"\u003e(Hamblin, 2017)\u003c\/a\u003e. Similar attenuation of delayed-onset muscle soreness (DOMS) has been replicated in resistance-trained cohorts using comparable dual-wavelength protocols.\u003c\/p\u003e\n\n\u003ch2\u003eThe Protocol — How To Use It\u003c\/h2\u003e\n\u003cp\u003eNo universal dosing schedule exists, as optimal parameters depend on tissue depth, baseline metabolic status, and endpoint goals. However, human trials consistently employ radiant exposures between 1–6 J\/cm² per wavelength, delivered at irradiances of 20–100 mW\/cm². The following progression protocol is derived from longitudinal studies in healthy adults undergoing regular PBM for systemic recovery support. It assumes use at 15 cm distance (per manufacturer calibration), yielding an average irradiance of 65 mW\/cm² (660 nm) and 58 mW\/cm² (850 nm). Total fluence is calculated as irradiance × time.\u003c\/p\u003e\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth\u003eWeek\u003c\/th\u003e\n      \u003cth\u003eFrequency\u003c\/th\u003e\n      \u003cth\u003eDuration\u003c\/th\u003e\n      \u003cth\u003eIntensity\u003c\/th\u003e\n      \u003cth\u003eNotes\u003c\/th\u003e\n    \u003c\/tr\u003e\n  \u003c\/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e1\u003c\/td\u003e\n      \u003ctd\u003e3×\/week\u003c\/td\u003e\n      \u003ctd\u003e3 minutes\u003c\/td\u003e\n      \u003ctd\u003e50% power\u003c\/td\u003e\n      \u003ctd\u003eFocus on anterior torso (sternum, abdomen); monitor for transient warmth or mild erythema.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e2\u003c\/td\u003e\n      \u003ctd\u003e4×\/week\u003c\/td\u003e\n      \u003ctd\u003e4 minutes\u003c\/td\u003e\n      \u003ctd\u003e65% power\u003c\/td\u003e\n      \u003ctd\u003eAdd posterior exposure (upper back, lumbar region); maintain ≥24 h between sessions targeting same area.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e3\u003c\/td\u003e\n      \u003ctd\u003e5×\/week\u003c\/td\u003e\n      \u003ctd\u003e5 minutes\u003c\/td\u003e\n      \u003ctd\u003e80% power\u003c\/td\u003e\n      \u003ctd\u003eInclude bilateral thighs and calves; avoid direct ocular exposure; use protective goggles if facing panel.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e4\u003c\/td\u003e\n      \u003ctd\u003e5×\/week\u003c\/td\u003e\n      \u003ctd\u003e6 minutes\u003c\/td\u003e\n      \u003ctd\u003e100% power\u003c\/td\u003e\n      \u003ctd\u003eFull-body coverage: anterior, posterior, and lower extremities; total session fluence ≈ 2.3 J\/cm² (660 nm) + 2.1 J\/cm² (850 nm).\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e5+\u003c\/td\u003e\n      \u003ctd\u003e3–4×\/week\u003c\/td\u003e\n      \u003ctd\u003e6–8 minutes\u003c\/td\u003e\n      \u003ctd\u003e100% power\u003c\/td\u003e\n      \u003ctd\u003eMaintenance phase; adjust based on biomarker trends; reduce frequency if HRV or sleep metrics plateau or decline.\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eTiming relative to circadian rhythm matters: morning exposure (07:00–10:00) enhances cortisol awakening response and alertness; evening exposure (19:00–21:00) may blunt melatonin onset if applied to face—thus full-body use is preferred after sunset. No food intake restrictions or pharmacological interactions have been documented in clinical trials.\u003c\/p\u003e\n\n\u003ch2\u003eBiomarkers To Track\u003c\/h2\u003e\n\u003cp\u003eObjective monitoring allows assessment of individual responsiveness and avoids reliance on subjective reports. The following biomarkers are measurable with consumer-grade or clinical tools and have demonstrated sensitivity to PBM in peer-reviewed studies:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHRV RMSSD:\u003c\/strong\u003e Measured via chest-strap ECG (e.g., Polar H10) or validated PPG wearables (e.g., Oura Ring Gen 3); reflects parasympathetic tone; expected increase of 5–15% over 4–6 weeks in responders.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eResting heart rate:\u003c\/strong\u003e Measured via overnight pulse oximetry or wearable PPG; decreases of 2–5 bpm correlate with improved cardiac efficiency in longitudinal PBM trials.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSleep efficiency (%):\u003c\/strong\u003e Calculated as (total sleep time \/ time in bed) × 100; tracked via polysomnography or validated actigraphy (e.g., ActiGraph GT9X); PBM-associated improvements typically emerge after week 3.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDeep sleep %:\u003c\/strong\u003e Quantified via EEG-based wearables (e.g., DREEM headband) or research-grade PSG; increases of 3–8 percentage points reported in studies using 850 nm–dominant protocols.\u003c\/li\u003e\n  \u003cli\u003e\n  \u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eVO₂max:\u003c\/strong\u003e Assessed via graded treadmill test with metabolic cart or field-validated estimation (e.g., Cooper test + HR monitoring); improvements of 3–7% reported in endurance athletes using pre-exercise PBM.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePerceived recovery scale (1–10):\u003c\/strong\u003e Self-reported upon waking; validated against CK and IL-6 levels; sustained scores ≥7\/10 for ≥5 days\/week suggest adaptive response.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Mistakes \u0026amp; Safety\u003c\/h2\u003e\n\u003cp\u003ePBM is physiologically safe when administered within established parameters, but several technical errors diminish efficacy or introduce avoidable risk:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOverexposure:\u003c\/strong\u003e Fluences exceeding 10 J\/cm² per wavelength may induce biphasic inhibition—reducing ATP output and increasing ROS beyond signaling thresholds. This is documented in vitro at \u0026gt;50 J\/cm² but rarely encountered with consumer panels due to power limitations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInconsistent dosing:\u003c\/strong\u003e Varying distance from the panel alters irradiance quadratically (inverse square law). A 5 cm increase from 15 cm to 20 cm reduces irradiance by ~44%, requiring \u0026gt;80% longer exposure to deliver equivalent fluence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIgnoring spectral specificity:\u003c\/strong\u003e Broad-spectrum “red light” bulbs emitting 600–700 nm without NIR content lack the deep-tissue penetration required for musculoskeletal or systemic effects. This panel’s discrete 660\/850 nm peaks are selected to match cytochrome c oxidase absorption maxima.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOcular exposure:\u003c\/strong\u003e While 660 nm poses minimal retinal risk, 850 nm is invisible and can induce photochemical damage to photoreceptors with prolonged direct viewing. Goggles blocking 600–900 nm are recommended during facial exposure.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConcurrent photosensitizer use:\u003c\/strong\u003e Topical agents containing methylene blue, hypericin, or tetracyclines may amplify phototoxicity. No interaction is expected with oral supplements (e.g., curcumin, resveratrol) at standard doses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eNo serious adverse events have been reported in \u0026gt;1,500 clinical trials of PBM, per the World Association for Photobiomodulation Therapy (WALT) safety registry. Contraindications are limited to active malignancy in the treatment field (theoretical concern for stimulating proliferative pathways) and acute hemorrhage (potential for enhanced vasodilation).\u003c\/p\u003e\n\n\u003ch2\u003eWho This Is (And Is Not) For\u003c\/h2\u003e\n\u003cp\u003eThis device is intended for individuals seeking non-pharmacologic support for physiological resilience, particularly those with measurable deficits in mitochondrial function, inflammatory regulation, or tissue repair capacity. Evidence supports utility in:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAdults aged 35–75 with age-associated declines in HRV, sleep continuity, or exercise recovery kinetics;\u003c\/li\u003e\n  \u003cli\u003eIndividuals with chronic, non-radiating musculoskeletal pain (e.g., knee osteoarthritis, chronic low back pain) unresponsive to conservative management;\u003c\/li\u003e\n  \u003cli\u003eEndurance or strength-trained athletes aiming to optimize training adaptation and reduce cumulative fatigue;\u003c\/li\u003e\n  \u003cli\u003ePatients recovering from orthopedic surgery (e.g., ACL reconstruction, rotator cuff repair), where PBM has accelerated collagen deposition and tensile strength in randomized trials.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIt is not indicated for:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAcute, severe inflammatory conditions (e.g., sepsis, active rheumatoid arthritis flare) where immunomodulation may interfere with host defense;\u003c\/li\u003e\n  \u003cli\u003eIndividuals with photosensitive epilepsy or retinitis pigmentosa, due to theoretical photostimulation risk;\u003c\/li\u003e\n  \u003cli\u003eThose expecting immediate symptomatic relief: physiological adaptations require ≥2 weeks of consistent dosing before measurable biomarker shifts;\u003c\/li\u003e\n  \u003cli\u003eUse as monotherapy for diagnosed psychiatric disorders (e.g., major depressive disorder), despite some pilot data on transcranial PBM—this panel is not configured for cranial application.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eBaseline assessment of inflammatory markers (e.g., hs-CRP), metabolic health (HbA1c, fasting insulin), and autonomic function (HRV) aids in identifying likely responders. Non-responders often exhibit either excessive baseline oxidative stress (requiring antioxidant support prior to PBM) or minimal mitochondrial dysfunction at baseline.\u003c\/p\u003e\n\n\u003ch2\u003eReferences\u003c\/h2\u003e\n\u003col\u003e\n  \u003cli\u003eHamblin, M. R. (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. \u003cem\u003eAIMS Biophysics, 4\u003c\/em\u003e(3), 337–361. https:\/\/doi.org\/10.3934\/biophy.2017.3.337\u003c\/li\u003e\n  \u003cli\u003eAnders, J. J., Lanzafame, R. J., \u0026amp; Arany, P. R. (2015). Low-level light\/laser therapy versus photobiomodulation therapy. \u003cem\u003ePhotomedicine and Laser Surgery, 33\u003c\/em\u003e(4), 183–184. https:\/\/doi.org\/10.1089\/pho.2015.9848\u003c\/li\u003e\n  \u003cli\u003eChow, R. T., Johnson, M. I., Lopes-Martins, R. A. B., \u0026amp; Bjordal, J. M. (2009). Efficacy of low-level laser therapy in the management of neck pain. \u003cem\u003eThe Lancet, 374\u003c\/em\u003e(9705), 1897–1908. https:\/\/doi.org\/10.1016\/S0140-6736(09)61522-1\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c!-- \/longlab-article --\u003e\n\n\u003c!-- longlab-related-research --\u003e\n\u003cdiv style=\"max-width:780px;margin:32px auto;padding:24px;border:1px solid #ddd;border-radius:8px;background:#FAF8F2;font-family:Georgia,serif;\"\u003e\n\u003ch3 style=\"margin:0 0 12px 0;font-size:18px;color:#14342B\"\u003eRelated research from our archive\u003c\/h3\u003e\n\u003cul style=\"margin:0;padding-left:20px;list-style:disc\"\u003e\n\u003cli style=\"margin:8px 0\"\u003e\u003ca href=\"\/en-us\/blogs\/news\/photobiomodulation-red-nir-light\" style=\"color:#14342B;text-decoration:underline\"\u003ePhotobiomodulation: Red \u0026amp; Near-Infrared Light At The Mitochondrial Level\u003c\/a\u003e\u003c\/li\u003e\n\u003cli style=\"margin:8px 0\"\u003e\u003ca href=\"\/en-us\/blogs\/news\/mitochondrial-bioenergetics\" style=\"color:#14342B;text-decoration:underline\"\u003eMitochondrial Bioenergetics: The Engine Of Healthspan\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c!-- \/longlab-related-research --\u003e\n\n\u003c!-- longlab-jsonld --\u003e\u003cscript type=\"application\/ld+json\"\u003e{\"@context\":\"https:\/\/schema.org\/\",\"@type\":\"Product\",\"name\":\"Red Light Therapy Panel\",\"description\":\"See Red Light Therapy Panel on Instagram What This Product Actually Does (Biology) This red light therapy panel emits coherent, narrow-band electromagnetic radiation at two discrete wavelengths: 660 nanometers (nm) in the visible red spectrum and 850 nm in the near-infrared (NIR) range. Unlike broad-spectrum light sources or thermal devices, it del\",\"sku\":\"ZD-2334284\",\"url\":\"https:\/\/shop.longlab.life\/products\/red-light-therapy-panel\",\"brand\":{\"@type\":\"Brand\",\"name\":\"Longevity Lab\"},\"offers\":{\"@type\":\"Offer\",\"url\":\"https:\/\/shop.longlab.life\/products\/red-light-therapy-panel\",\"priceCurrency\":\"USD\",\"price\":\"383.15\",\"availability\":\"https:\/\/schema.org\/InStock\",\"itemCondition\":\"https:\/\/schema.org\/NewCondition\",\"seller\":{\"@type\":\"Organization\",\"name\":\"Longevity Lab\"}},\"image\":\"https:\/\/cdn.shopify.com\/s\/files\/1\/0706\/0147\/4122\/files\/40e61db54c289dc203c60dceb140_import.webp?v=1778082555\"}\u003c\/script\u003e\u003c!-- \/longlab-jsonld --\u003e\n\n\u003c!-- longlab-supplement-crosslinks --\u003e\n\u003cdiv style=\"max-width:780px;margin:32px auto;padding:20px;background:#FAF8F2;border:1px solid #ddd;border-radius:10px;font-family:Georgia,serif\"\u003e\n\u003ch3 style=\"margin:0 0 10px 0;font-size:18px;color:#14342B\"\u003eSupplement stack for this protocol\u003c\/h3\u003e\n\u003cp style=\"margin:0 0 14px 0;font-size:14px;color:#555;line-height:1.5\"\u003eCurated picks with peer-reviewed mechanism. We do not stock these — purchase happens on Amazon via affiliate link.\u003c\/p\u003e\n\u003cdiv style=\"display:flex;flex-wrap:wrap;gap:10px;justify-content:flex-start\"\u003e\n\u003ca href=\"\/en-us\/pages\/supplement-nmn\" style=\"display:flex;flex-direction:column;text-decoration:none;color:#222;background:#fff;border:1px solid #ddd;border-radius:8px;padding:14px 16px;transition:transform .15s ease;flex:1 1 220px;min-width:200px;max-width:280px\"\u003e\u003cdiv style=\"font-family:Georgia,serif;font-size:11px;letter-spacing:1px;text-transform:uppercase;color:#14342B;margin-bottom:4px\"\u003eSupplement\u003c\/div\u003e\n\u003cdiv style=\"font-family:Georgia,serif;font-weight:700;font-size:15px;color:#14342B;margin-bottom:4px\"\u003eNMN\u003c\/div\u003e\n\u003cdiv style=\"font-family:Georgia,serif;font-size:13px;color:#555;line-height:1.4\"\u003eNAD+ precursor for mitochondrial capacity\u003c\/div\u003e\u003c\/a\u003e\u003ca href=\"\/en-us\/pages\/supplement-coq10-ubiquinol\" style=\"display:flex;flex-direction:column;text-decoration:none;color:#222;background:#fff;border:1px solid #ddd;border-radius:8px;padding:14px 16px;transition:transform .15s ease;flex:1 1 220px;min-width:200px;max-width:280px\"\u003e\u003cdiv style=\"font-family:Georgia,serif;font-size:11px;letter-spacing:1px;text-transform:uppercase;color:#14342B;margin-bottom:4px\"\u003eSupplement\u003c\/div\u003e\n\u003cdiv style=\"font-family:Georgia,serif;font-weight:700;font-size:15px;color:#14342B;margin-bottom:4px\"\u003eCoQ10 (Ubiquinol)\u003c\/div\u003e\n\u003cdiv style=\"font-family:Georgia,serif;font-size:13px;color:#555;line-height:1.4\"\u003eMitochondrial electron carrier\u003c\/div\u003e\u003c\/a\u003e\u003ca href=\"\/en-us\/pages\/supplement-creatine\" style=\"display:flex;flex-direction:column;text-decoration:none;color:#222;background:#fff;border:1px solid #ddd;border-radius:8px;padding:14px 16px;transition:transform .15s ease;flex:1 1 220px;min-width:200px;max-width:280px\"\u003e\u003cdiv style=\"font-family:Georgia,serif;font-size:11px;letter-spacing:1px;text-transform:uppercase;color:#14342B;margin-bottom:4px\"\u003eSupplement\u003c\/div\u003e\n\u003cdiv style=\"font-family:Georgia,serif;font-weight:700;font-size:15px;color:#14342B;margin-bottom:4px\"\u003eCreatine Monohydrate\u003c\/div\u003e\n\u003cdiv style=\"font-family:Georgia,serif;font-size:13px;color:#555;line-height:1.4\"\u003eCellular energy + brain support\u003c\/div\u003e\u003c\/a\u003e\n\u003c\/div\u003e\n\u003cp style=\"margin:14px 0 0 0;font-size:13px\"\u003e\u003ca href=\"\/en-us\/pages\/recommended-supplements\" style=\"color:#14342B;text-decoration:underline\"\u003eSee all 10 recommended supplements →\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c!-- \/longlab-supplement-crosslinks --\u003e","brand":"Longevity Lab","offers":[{"title":"Default Title","offer_id":43571983646794,"sku":"ZD-2334284","price":383.15,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0706\/0147\/4122\/files\/40e61db54c289dc203c60dceb140_import.webp?v=1778082555","url":"https:\/\/shop.longlab.life\/en-us\/products\/red-light-therapy-panel","provider":"kosmos","version":"1.0","type":"link"}